TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

PHASE3CompletedINTERVENTIONAL
Enrollment

292

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
PregnancyThrombophiliaPregnancy Complications
Interventions
DRUG

dalteparin sodium

"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"

Trial Locations (12)

63117

Saint Louis University, St Louis

84132

University of Utah Health Sciences Centre, Salt Lake City

Unknown

Royal Alexandra Hospital, Edmonton

QEII Health Sciences Centre, Halifax

Hamilton Health Sciences Centre, Hamilton

The Ottawa Hospital, Civic Campus, Ottawa

Mount Sinai Hospital, Toronto

Women's College Health Sciences Centre, Toronto

SMBD Jewish General Hospital, Montreal

St Mary's Hospital Centre, Montreal

CHA, Hopital Enfant Jesus, Québec

Royal University Hospital, Saskatoon

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Hospital Research Institute

OTHER